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Abstract The objectives of this study were to evaluate
the reliability of Bath ankylosing spondylitis functional
index (BASFI) and Bath ankylosing spondylitis disease
activity index (BASDAI) in Chinese ankylosing spondy-
litis (AS) and undifferentiated spondyloarthropathy
(USpA) patients. 664 AS patients by the revised New
York criteria for AS and 252 USpA patients by the
European Spondyloarthropathy Study Group criteria were
enrolled. BASDAI and BASFI questionnaires were
translated into Chinese. Participants were required to ﬁll
in BASFI and BASDAI questionnaires again after 24 h.
Moreover, BASDAI and BASFI were compared in AS
patients receiving Enbrel or inﬂiximab before and after
treatment. For AS group, BASDAI ICC: 0.9502 (95% CI:
0.9330–0.9502, a = 0.9702), BASFI ICC: 0.9587 (95%
CI: 0.9521–0.9645, a = 0.9789). For USpA group, BAS-
DAI ICC: 0.9530 (95% CI: 0.9402–0.9632, a = 0.9760),
BASFI ICC: 0.9900 (95% CI: 0.9871–0.9922,
a = 0.9950). In the AS group, disease duration, occipital
wall distance, modiﬁed Schober test, chest expansion,
ESR, and CRP showed signiﬁcant correlation with BAS-
DAI and BASFI (all P\0.01). In the USpA group, onset
age, ESR, and CRP were signiﬁcantly correlated with
BASDAI (all P\0.05), while modiﬁed Schober test,
ESR, and CRP were signiﬁcantly associated with BASFI
(all P\0.05). The change in BASDAI and BASFI via
Enbrel or inﬂiximab treatment showed a signiﬁcant
positive correlation (P\0.01). The two instruments have
good reliability and reference value regarding the evalu-
ation of patient’s condition and anti-TNF-a treatment
response.
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As a subtype of spondyloarthropathy (SpA), ankylosing
spondylitis (AS) is a chronic inﬂammatory disorder of
unknown etiology mainly affecting the spine and sacro-
iliac joints. The major clinical manifestations of AS
include inﬂammatory back pain, morning stiffness, and
limited spinal activity and/or concurrent peripheral
arthritis and enthesitis and even spinal deformity or
ankylosis at the advanced stage. Physical disability occurs
in about one-third of AS patients within 15–20 years after
the diagnosis [1]. There are many evaluation tools for AS,
and the Bath ankylosing spondylitis functional index
(BASFI) and disease activity index (BASDAI) are the
most common tools used to assess patients suffering from
AS. Other objective indicators include occipital wall
distance, modiﬁed Schober test, chest expansion, and
lateral ﬂexion [2–5].
BASDAI and BASFI are often used to evaluate the
USpA condition in some countries. However, it remains to
be validated whether BASFI and BASDAI are also appli-
cable in different countries and regions. Undifferentiated
spondyloarthropathy (USpA) is the most common SpA
subtype also characterized by inﬂammatory back pain and
arthritis, and it does not conform to the criteria for AS,
Reiter’s syndrome, psoriatic arthritis or inﬂammatory
bowel disease arthritis [6]. Here, we conducted this pro-
spective, multi-center study to explore the reliability and
reference value of BASDAI and BASFI in the evaluation
of patient’s condition and treatment response in China for
the ﬁrst time.
Patients and methods
Patients
The survey involved 664 AS patients and 252 USpA
patients from eight centers (Department of Rheumatology,
Third Afﬁliated Hospital of Sun Yat-sen University,
Guangzhou;DepartmentofRheumatology,TongjiHospital,
Tongji Medical College, Central China University of
Science and Technology, Hubei; Department of Rheu-
matology, Xiangya Second Afﬁliated Hospital, Central
South University, Hunan; Department of Rheumatology,
Xiangya First Afﬁliated Hospital, Central South Univer-
sity, Hunan; Shenzhen Rheumatology Institute of Guang-
dong Medical College; Department of Rheumatology,
Henan Provincial People’s Hospital; Department of
Rheumatology, Hainan Provincial People’s Hospital;
Department of Rheumatology, Guangxi Zhuangzu Auton-
omous Region People’s Hospital; China) over 6 years
(2002–2007).
Questionnaires
Bath ankylosing spondylitis disease activity index (BAS-
DAI): The index consists of six ‘‘10-cm’’ horizontal visual
analog scales (VAS) to evaluate severity of fatigue, spinal
and peripheral joint pain, localized tenderness, and morn-
ing stiffness [3]. A score of 0 means no symptoms, and a
score of 10 means very severe symptoms. A mean score is
calculated across all items. The range is from 0 to 10.
Bath ankylosing spondylitis functional index (BASFI):
Ten items are included concerning the respondents’ per-
ception of their functional ability and how well they are
able to function in everyday life. 0–10 cm on a visual
analog scale describes the current condition [2]. The mean
score is calculated across all items (range 0–10).
Translation
The BASDAI and BASFI questionnaires were translated
into Chinese by two independent bilingual physicians who
were familiar with the medical aspects of AS and by one
professional translator. Two rheumatologists familiar with
instrument validation and aware of the purpose of the study
examined semantic, idiomatic, and conceptual issues.
English back-translation from the Chinese was done by a
professional translator unaware of the original version.
Both English versions were compared and necessary
modiﬁcations to the Chinese versions were made to reach
an agreement.
Assessment
First of all, the diagnosis was conﬁrmed by an expert in
rheumatology from each center according to the revised
1984 New York criteria for AS and European Spond-
yloarthropathy Study Group (ESSG) criteria for USpA; and
then a full-time rheumatologist in the corresponding center
conducted face-to-face interview. The survey includes
demography, BASFI, BASDAI, spinal activity index
(modiﬁed Schober’s test, lateral ﬂexion, occipital wall
distance, and chest expansion) and laboratory indicator
such as HLA-B27, erythrocyte sedimentation rate (ESR)
and C-reactive protein (CRP), as well as sacroiliac joint
X-ray change (conducted within 2 months); 24 h after
ﬁlling the form, without any drug treatment, the patients
were retested using BASFI, BASDAI questionnaire, and
the average score was used for further analysis. In addition,
39 active AS patients were administered Enbrel (50 mg,
subcutaneous injection, once a week) and 107 active AS
patients received inﬂiximab (5 mg/kg, venous injection, at
weeks 0, 2, and 6) for a total of 6 weeks. After 6-week
Enbrel or inﬂiximab treatment, the BASDAI and BASFI
were recorded and compared. By correlation analysis
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123between BASFI and other parameters [5], we assessed the
reliability and validity of BASFI and BASDAI in Chinese
AS and USpA patients.
Statistical analysis
Data were expressed as mean ± standard deviation
(x ± SD, 95% CI). Intraclass correlation coefﬁcient (ICC)
for agreement (reliability) and consistency was calculated,
and alpha statistic was calculated as an additional measure
of reliability (a[0.75: very good test–retest reliability,
0.4–0.75: good test–retest reliability, a\0.4: poor test–
retest reliability). Validation was tested by calculation of
Spearman’s correlation coefﬁcient (r) between various
parameters. P\0.05 was considered statistically signiﬁ-
cant. All data and statistical manipulation were processed
using SPSS 12.0.
Results
Clinical data
AS patients (664): male:female = 6.9:1, average age:
30.0 ± 9.3 years, average onset age: 21.7 ± 7.2 years,
average duration: 7.2 ± 6.7 years, family history: 18.4%
(n = 122), HLA-B27 (?): 90.2% (n = 599).
USpA patients (252): male:female = 2.0:1, average age:
26.0 ± 9.3 years, average onset age: 22.7 ± 7.7 years,
average duration: 2.9 ± 3.4 years, family history: 19.8%
(n = 50), HLA-B27 (?): 67.9% (n = 171).
Reliability of BASDAI and BASFI
Reliability showed an acceptable 24-h test–retest ICC. In
the AS group, BASDAI ICC: 0.9502 (95% CI: 0.9330–
0.9502, a = 0.9702), BASFI ICC: 0.9587 (95% CI:
0.9521–0.9645, a = 0.9789). In USpA group, BASDAI
ICC: 0.9530 (95% CI: 0.9402–0.9632, a = 0.9760),
BASFI ICC: 0.9900 (95% CI: 0.9871–0.9922, a = 0.9950)
.
Correlation analysis between BASDAI, BASFI,
and other clinical parameters
As shown in Table 1, in the AS group, the duration,
occipital wall distance, modiﬁed Schober’s test, ESR, and
CRP were signiﬁcantly associated with BASDAI and
BASFI (all P\0.01), but we found no correlation between
age at onset and BASDAI or BASFI. Table 2 showed that
age at onset, ESR, and CRP were signiﬁcantly associated
with BASDAI (all P\0.05), and modiﬁed Schober’s test,
ESR, and CRP were signiﬁcantly correlated with BASFI
(all P\0.05).
BASDAI and BASFI correlation
The BASDAI and BASFI demonstrated signiﬁcant positive
correlationbothin ASgroup(Fig. 1,r = 0.587,P = 0.000)
and in USpA group (Fig. 2, r = 0.590, P = 0.000).
BASDAI and BASFI changes via 6-week TNF-a
antagonist treatment
We enrolled 39 active AS patients and kept record of their
BASDAI (4.92 ± 1.75 vs. 2.82 ± 1.65) and BASFI
(3.99 ± 2.34 vs. 2.15 ± 2.03) score at weeks 0 and 6 with
Enbrel therapy. The changes between two index were
statistically correlated (Fig. 3, r = 0.778, P = 0.000). In
addition, we analyzed the change of BASDAI (4.31 ± 1.6
vs. 0.96 ± 1.1) and BASFI (2.40 ± 2.26 vs. 0.67 ± 1.11)
in 107 USpA patients receiving inﬂiximab for 6 weeks, and
results showed that BASDAI and BASFI also improved,
and their changes after treatment showed a weak positive
correlation(r = 0.345, P = 0.000).
Table 1 Correlation between BASDAI, BASFI, and other clinical
parameters in AS
BASDAI BASFI
RP r P
Age at onset (years) 0.072 0.072 0.056 0.162
Duration (years) 0.149 0.000 0.145 0.000
Occipital wall distance (cm) 0.159 0.000 0.308 0.000
Modiﬁed Schober’s test (cm) -0.214 0.000 -0.308 0.000
Chest expansion (cm) -0.183 0.000 -0.227 0.000
ESR (mm/h) 0.263 0.000 0.295 0.000
CRP (mg/L) 0.231 0.000 0.359 0.000
r Spearman’s correlation coefﬁcient
Table 2 Correlation between BASDAI, BASFI, and other clinical
parameters in USpA
BASDAI BASFI
RP r P
Age at onset (years) 0.204 0.001 -0.073 0.249
Duration (years) 0.116 0.670 0.020 0.752
Modiﬁed Schober’s test (cm) -0.109 0.860 -0.314 0.000
Chest expansion (cm) 0.023 0.716 0.024 0.702
ESR (mm/h) 0.142 0.025 0.357 0.000
CRP (mg/L) 0.211 0.001 0.336 0.000
r Spearman’s correlation coefﬁcient
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BASFI and BASDAI are two important tools used to assess
the impact of AS on the quality of life dimensions of a
patients with AS. In terms of the worldwide distribution of
AS and the need for uniﬁed disease activity and functional
indexes, those tools have to be adapted to different nations.
The study aimed at assessing validity and reliability of the
cross-culturally adapted versions of the BASFI and
BASDAI.
BASDAI and BASFI questionnaires are widely used to
evaluate disease activity and physical function, respec-
tively, in patients with AS, and both are often applied in
medical and clinical researches. The reliability of both
questionnaires in evaluating AS has been validated by
studies in some countries [7–11]. However, the validity of
BASDAI and BASFI in patients with USpA was seldom
investigated except that Cardiel et al. [9] mentioned it in a
study involving 61 AS and 80 USpA patients in 2003.
Additionally, in China, the reliability of these two instru-
ments is still unclear, although they have been used in
clinical and medical research for many years. In this study,
the data coming from multi centers are representatives of
the population. Results suggested that test–retest ICC for
BASDAI and BASFI in patients with AS and USpA were
similar to that in previous studies [7–11]; a[0.75 in
Chinese AS and USpA groups indicated that the two
instruments have very good reliability and are well worth
promoting.
In this study, we analyzed the correlation between
BASDAI, BASFI and other clinical parameters using
Spearman’s correlation coefﬁcient (r). In the AS group
(Table 1), the disease duration, occipital wall distance,
modiﬁed Schober’s test, chest expansion, ESR, and CRP
were signiﬁcantly associated with BASDAI and BASFI,
but we found no correlation between age at onset and
BASDAI or BASFI. In the USpA group (Table 2), the age
at onset, ESR, and CRP were signiﬁcantly associated with
BASDAI, and modiﬁed Schober’s test, ESR, and CRP were
signiﬁcantly correlated with BASFI.
As for the BASDAI, our results suggest that: (1) In both
AS group and USpA group, CRP and ESR were signiﬁ-
cantly related to BASDAI, indicating that BASDAI could
reﬂect the disease activity of both USpA and AS patients,
consistent with a number of previous studies [7, 12, 13]. (2)
In AS patients, the disease duration also showed a positive
correlation with BASDAI, while USpA patients did not.
This may be due to a longer course of disease in patients
with AS, and some patients suffer even more than 10 years,
and have axial involvement, with more sites also involved,
leading to the increased BASDAI scores indicating
inﬂammatory activity. While USpA patients tend to have a
shorter duration, often less than 2 years, and not many
Fig. 1 The correlation between BASDAI and BASFI in AS
Fig. 2 The correlation between BASDAI and BASFI in USpA
Fig. 3 The correlation improvement between BASDAI and BASFI
with 6-week Enbrel therapy
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123patients have axial involvement, and fewer sites were
involved, that is to say, early in the course of disease,
patient’s symptoms are relatively slight or concealed.
Therefore, in such a short course of disease, the patient’s
inﬂammation indicators such as BASDAI scores did not
change signiﬁcantly. (3) In the AS group, modiﬁed Schober
test is also signiﬁcantly associated with the BASDAI but
not in USpA group. This may be because USpA patients
have shorter disease duration and no involvement of the
lumbar spine in general. (4) In USpA group, onset age is
also signiﬁcantly associated with the BASDAI, which may
be due to the earlier age of onset paralleling the more
obvious and severe symptoms, especially peripheral
symptoms, resulting in higher BASDAI; while for AS, the
impact of onset age on inﬂammation is quite eclipsed by
longer disease duration and more sites involved.
The results for the BASFI show that: (1) Most indicators
such as modiﬁed Schober test do not suit USpA patients,
since the vast majority of functions in those patients are
normal. But the correlation between BASFI for patients
with AS and the disease duration, occipital wall distance,
modiﬁed Schober’s test, and chest expansion, showing that
limited physical function of patients is also aggravating
with the longer duration. (2) For both AS and USpA group,
ESR and CRP show signiﬁcant correlation with BASFI,
suggesting that the inﬂammatory activity affects the motor
function partly.
All the above demonstrates that there is positive corre-
lation between BASDAI and BASFI. This indicates that
active inﬂammation has impact on physical function.
Last but not least, we also investigated the change in
BASDAI and BASFI score in the treatment of drug
responsiveness. Enbrel and Inﬂiximab are commonly used
anti-TNF-a biological agents in the treatment of AS, and its
remarkable effectiveness has been widely conﬁrmed
[14–20]. In this study, results showed that BASDAI and
BASFI in AS patients decreased signiﬁcantly after Enbrel
or inﬂiximab treatment, and results suggest that after
treatment, with the reduction of disease activity, physical
function also improved. Decreased value in BASDAI and
BASFI score also showed a clear correlation, indicating
that these two questionnaires could act as good evaluation
tools for therapeutic effect of Enbrel and inﬂiximab.
In conclusion, results of this study revealed that the
Chinese version of the questionnaires maintained all
the properties of the original English-language forms of the
instruments. The Chinese version of BASDAI and BASFI
were found to be valid, reliable; hence, these instruments
can be applied in the evaluation of patient’s condition and
anti-TNF treatment response.
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